Prospector
Profile
07.1415
|
| |
| Biotech Holdings Ltd. |
NAICS |
325400 |
| #160 - 3751 Shell Road
Richmond, British Columbia, Canada V6X 2W2 |
Description |
Pharmaceuticals Mfg. |
| (604) 295-1119 |
Employees |
0 |
| http://www.biotechltd.com/ |
Revenue |
CAD(mil) |
0.3360 |
| |
Income |
CAD(mil) |
-1.5340 |
| |
Assets |
CAD(mil) |
0.3140 |
| |
Liability |
CAD(mil) |
3.3230 |
| |
(for the year ended 2007-03-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Cinnamon Jang Willoughby & Company expressed doubts on the ability of Biotech Holdings Ltd. to continue as a going concern after auditing its financial statements. The Company has incurred recurring operating losses and has an accumulated deficit of $31,273,810 and a shareholders' deficiency of $3,009,011 at March 31, 2007.
|
| |
|
Intellectual Property:
The Company pursues a policy of seeking patent protection where possible for the valuable patentable subject matter of its proprietary technology. The Company believes that patent and trade secret protection is important in its business, and that its success will depend on the ability to obtain and enforce strong patents, to maintain trade secret protection and to operate without infringing the proprietary rights of others. The Company's Volkspharm Healthcare, Inc. subsidiary has patent applications pending in Canada on Sucanon for which the Company has been granted exclusive licensing rights to countries other than Asia Countries. [SEC Filing 20-F 09-28-07]
|
| |
|
Description:
Biotech Holdings is a pharmaceutical production and distribution company.
|
| |
|
Officers:
Robert B. Rieveley (Pres., CEO & Dir.); Gale Belding (EVP & Dir.); Lorne Brown (CFO); Johan de Rooy (Dir.); Cheryl Rieveley (Dir.); Art Cowie (Dir.); Ross Wilmot (Dir.)
|
| |
|
Auditor:
Cinnamon Jang Willoughby & Company
|
| |
|
Securities:
Common Stock-Symbol BIO.V; CDNX;
92,229,512 common shares outstanding as of March 31, 2007.
|
| |
| |
| |
| return to main page |
